Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 2/20 | 0.55 |
| ▸ | MDM4 | O15151 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.50 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29651368 | 1.00 | TLR2 (0.55) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL120503 | 1.00 | TLR2 (0.55) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL29750297 | 1.00 | TLR2 (0.55) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL13227676 | 1.00 | TLR2 (0.55) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL31217659 | 1.00 | TLR2 (0.55) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL29401774 | 1.00 | TLR2 (0.55) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL29350848 | 1.00 | TLR2 (0.55) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL20592524 | 0.94 | MDM2 (0.54) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL20592527 | 0.94 | MDM2 (0.54) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL29759454 | 0.94 | MDM2 (0.54) | TLR2MDM4TP53MDM2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115943151-A | Process for the preparation of GLP-1/glucagon dual agonists | 伊莱利利公司 | 2023-04-07 | — | — | CN | disclosed |
| US-11560407-B2 | FOXP3-binding peptides and uses thereof | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2023-01-24 | — | — | US | disclosed |
| CN-108794422-B | Heterocyclic compounds as PD-L1 inhibitors | 南京圣和药业股份有限公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-109280075-B | Peptide amide compound, preparation method and medical application thereof | 四川海思科制药有限公司 | 2022-05-20 | — | — | CN | disclosed |
| US-20200317733-A1 | FOXP3-BINDING PEPTIDES AND USES THEREOF | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2020-10-08 | — | — | US | disclosed |
| US-20200206301-A1 | JNK Inhibitor Molecules For Treatment Of Various Diseases | XIGEN INFLAMMATION LTD. (CY) | 2020-07-02 | — | — | US | disclosed |
| US-10654896-B2 | FoxP3-binding peptides and uses thereof | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2020-05-19 | — | — | US | disclosed |
| EP-3377515-B1 | GELATINASE INHIBITORS AND USE THEREOF | IPROTEOS S L (ES) | 2019-10-30 | — | — | EP | disclosed |
| US-10414797-B2 | Gelatinase inhibitors and use thereof | IPROTEOS S.L (ES) | 2019-09-17 | — | — | US | disclosed |
| US-20190276496-A1 | FOXP3-BINDING PEPTIDES AND USES THEREOF | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2019-09-12 | — | — | US | disclosed |
| US-20180319839-A1 | GELATINASE INHIBITORS AND USE THEREOF | IPROTEOS S.L (ES) | 2018-11-08 | — | — | US | disclosed |
| EP-3377515-A1 | GELATINASE INHIBITORS AND USE THEREOF | Iproteos S.L (ES) | 2018-09-26 | — | — | EP | disclosed |
| US-8883963-B2 | Peptidomimetics with glucagon antagonistic and GLP 1 agonistic activities | CADILA HEALTHCARE LIMITED (IN) | 2014-11-11 | — | — | US | disclosed |
| WO-2014033466-A1 | METHOD AND COMPOSITIONS FOR REMOVING ACID-LABILE PROTECTING GROUPS | STETSENKO DMITRY (GB) | 2014-03-06 | — | — | WO | disclosed |
| EP-2231701-B1 | PEPTIDOMIMETICS WITH GLUCAGON ANTAGONISTIC AND GLP-1 AGONISTIC ACTIVITIES | CADILA HEALTHCARE LTD (IN) | 2012-04-18 | — | — | EP | disclosed |
| US-20120021972-A1 | PEPTIDOMIMETICS WITH GLUCAGON ANTAGONISTIC AND GLP 1 AGONISTIC ACTIVITIES | CADILA HEALTHCARE LIMITED (IN) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414797-B2 | Gelatinase inhibitors and use thereof | MMP8, SERPINE1, MMP9 | TLR2 958/4885MDM4 4853/4885TP53 3194/4885 |
| US-20200317733-A1 | FOXP3-BINDING PEPTIDES AND USES THEREOF | CCR3, CCR4, CXCR3 | TLR2 1506/4885MDM4 1272/4885TP53 296/4885 |
| US-11560407-B2 | FOXP3-binding peptides and uses thereof | CCR3, CCR4, CXCR3 | TLR2 1506/4885MDM4 1272/4885TP53 296/4885 |
| US-20120021972-A1 | PEPTIDOMIMETICS WITH GLUCAGON ANTAGONISTIC AND GLP 1 AGONISTIC ACTIVITIES | GLP1R, GPR119, GIPR | TLR2 1355/4885MDM4 4752/4885TP53 3886/4885 |
| US-20180319839-A1 | GELATINASE INHIBITORS AND USE THEREOF | MMP8, SERPINE1, MMP9 | TLR2 958/4885MDM4 4853/4885TP53 3194/4885 |
| US-20190276496-A1 | FOXP3-BINDING PEPTIDES AND USES THEREOF | CCR3, CCR4, CXCR3 | TLR2 1506/4885MDM4 1272/4885TP53 296/4885 |
| US-10654896-B2 | FoxP3-binding peptides and uses thereof | CCR3, CCR4, CXCR3 | TLR2 1506/4885MDM4 1272/4885TP53 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.